In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report), with a price target of $1.50. The company’s shares closed yesterday at $0.63.
Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -28.8% and a 20.34% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spectrum Pharmaceuticals with a $4.83 average price target, which is a 661.47% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.
SPPI market cap is currently $121.3M and has a P/E ratio of -0.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
Read More on SPPI: